The role of donor hypertension and angiotensin II in the occurrence of early pancreas allograft thrombosis
Christophe Masset,Julien Branchereau,Fanny Buron,Georges Karam,Maud Rabeyrin,Karine Renaudin,Florent Le Borgne,Lionel Badet,Xavier Matillon,Christophe Legendre,Denis Glotz,Corinne Antoine,Magali Giral,Jacques Dantal,Diego Cantarovich,DIVAT Consortium,Lionel Badet,Maria Brunet,Fanny Buron,R#xe9;mi Cahen,Ricardo Codas,Sameh Daoud,Val#xe9;rie Dubois,Coralie Fournie,Arnaud Gr#xe9;goire,Alice Koenig,Charl#xe8;ne L#xe9;vi,Emmanuel Morelon,Claire Pouteil-Noble,Maud Rabeyrin,Thomas Rimmel#xe9;,Olivier Thaunat,Gilles Blancho,Julien Branchereau,Diego Cantarovich,Agn#xe8;s Chapelet,Jacques Dantal,Cl#xe9;ment Deltombe,Lucile Figueres,Raphael Gaisne,Claire Garandeau,Magali Giral,Caroline Gourraud-Vercel,Maryvonne Hourmant,Georges Karam,Clarisse Kerleau,Delphine Kervella,Christophe Masset,Aur#xe9;lie Meurette,Simon Ville,Christine Kandell,Anne Moreau,Karine Renaudin,Florent Delbos,Alexandre Walencik,Anne Devis,Lucile Amrouche,Dany Anglicheau,Olivier Aubert,Lynda Bererhi,Christophe Legendre,Alexandre Loupy,Frank Martinez,Arnaud M#xe9;jean,R#xe9;becca Sberro-Soussan,Anne Scemla,Marc-Olivier Timsit,Julien Zuber,Gillian Divard,Carmen Lefaucheur,Denis Glotz
DOI: https://doi.org/10.3389/fimmu.2024.1359381
IF: 7.3
2024-05-18
Frontiers in Immunology
Abstract:Background: About 10–20% of pancreas allografts are still lost in the early postoperative period despite the identification of numerous detrimental risk factors that correlate with graft thrombosis. Methods: We conducted a multicenter study including 899 pancreas transplant recipients between 2000 and 2018. Early pancreas failure due to complete thrombosis, long-term pancreas, kidney and patient survivals were analyzed and adjusted to donor, recipient and perioperative variables using a multivariate cause-specific Cox model stratified to transplant centers. Results: Pancreas from donors with history of hypertension (6.7%), as well as with high body mass index (BMI), were independently associated with an increased risk of pancreas failure within the first 30 post-operative days (respectively, HR= 2.57, 95% CI from 1.35 to 4.89 and HR= 1.11, 95% CI from 1.04 to 1.19). Interaction term between hypertension and BMI was negative. Donor hypertension also impacted long-term pancreas survival (HR= 1.88, 95% CI from 1.13 to 3.12). However, when pancreas survival was calculated after the postoperative day 30, donor hypertension was no longer a significant risk factor (HR= 1.22, 95% CI from 0.47 to 3.15). A lower pancreas survival was observed in patients receiving a pancreas from a hypertensive donor without RAAS (Renin Angiotensin Aldosterone System) blockers compared to others (50% vs 14%, p < 0.001). Pancreas survival was similar among non-hypertensive donors and hypertensive ones under RAAS blockers. Conclusion: Donor hypertension was a significant and independent risk factor of pancreas failure. The well-known pathogenic role of renin-angiotensin-aldosterone system seems to be involved in the genesis of this immediate graft failure.
immunology